Pharmacophore modeling, comprehensive 3D-QSAR, and binding mode analysis of TGR5 agonists

References

• Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009;30:570–80.
   PubMed Web of Science ®Google Scholar
• Zou Q, Duan H, Ning M, et al. 4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists. Eur J Med Chem 2014;82:1–15.
   PubMed Web of Science ®Google Scholar
• Zhu J, Ning M, Guo C, et al. Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold. Eur J Med Chem 2013;69:55–68.
   PubMed Web of Science ®Google Scholar
• Baptissart M, Vega A, Maqdasy S, et al. Bile acids: from digestion to cancers. Biochimie 2013;95:504–17.
   PubMed Web of Science ®Google Scholar
• Budzik BW, Evans KA, Wisnoski DD, et al. Synthesis and structure–activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists. Bioorg Med Chem Lett 2010;20:1363–7.
   PubMed Web of Science ®Google Scholar
• Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10:167–77.
   PubMed Web of Science ®Google Scholar
• Park EJ, Ahn YG, Jung SH, et al. Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists. Bioorg Med Chem Lett 2014;24:4271–5.
   PubMed Web of Science ®Google Scholar
• Duan H, Ning M, Chen X, et al. Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists. J Med Chem 2012;55:10475–89.
   PubMed Web of Science ®Google Scholar
• Kumar DP, Rajagopal S, Mahavadi S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem Biophys Res Commun 2012;427:600–5.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Baldelli F. Farnesoid X receptor agonists in biliary tract disease. Curr Opin Gastroenterol 2009;25:252–9.
   PubMed Web of Science ®Google Scholar
• Tan KP, Yang M, Ito S. Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress. Mol Pharmacol 2007;72:1380–90.
   PubMed Web of Science ®Google Scholar
• Londregan AT, Piotrowski DW, Futatsugi K, et al. Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries. Bioorg Med Chem Lett 2013;23:1407–11.
   PubMed Web of Science ®Google Scholar
• Phase, version 3.8. New York (NY): Schrödinger, LLC; 2014.
   Google Scholar
• LigPrep, version 2.9. New York (NY): Schrödinger, LLC; 2014.
   Google Scholar
• Jorgenson WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS All-Atom Force Field on conformational energies and properties of organic liquids. J Am Chem Soc 1996;118:11223–36.
   Web of Science ®Google Scholar
• Canvas, version 2.6. New York (NY): Schrödinger, LLC; 2015.
   Google Scholar
• Huang N, Shoichet BK, Irwin JJ. Benchmarking sets for molecular docking. J Med Chem 2006;49:6789–801.
   PubMed Web of Science ®Google Scholar
• Sindhu T, Srinivasan P. Exploring the binding properties of agonists interacting with human TGR5 using structural modeling, molecular docking and dynamics simulations. RSC Adv 2015;5:14202–13.
   Web of Science ®Google Scholar
• Farid R, Day T, Friesner RA, Pearlstein RA. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg Med Chem 2006;14:3160–73.
   PubMed Web of Science ®Google Scholar
• Prime, version 3.5. New York (NY): Schrödinger, LLC; 2014.
   Google Scholar
• Lyne PD, Lamb ML, Saeh JC. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem 2006;49:4805–8.
   PubMed Web of Science ®Google Scholar
• Saxena S, Devi PB, Soni V, et al. Identification of novel inhibitors against Mycobacterium tuberculosis l-alanine dehydrogenase (MTB-AlaDH) through structure-based virtual screening. J Mol Graph Model 2014;47:37–43.
   PubMed Web of Science ®Google Scholar
• Ambure P, Kar S, Roy K. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer’s agents. Biosystems 2014;116:10–20.
   PubMed Web of Science ®Google Scholar
• Sastry M, Lowrie JF, Dixon SL, Sherman W. Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments. J Chem Inf Model 2010;50:771–84.
   PubMed Web of Science ®Google Scholar
• Bender A, Mussa HY, Glen RC, Reiling S. Molecular similarity searching using atom environments, information-based feature selection, and a naïve Bayesian classifier. J Chem Inf Comput Sci 2004;44:170–8.
   PubMedGoogle Scholar
• Bender A, Mussa HY, Glen RC, Reiling S. Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): evaluation of performance. J Chem Inf Comput Sci 2004;44:1708–18.
   PubMedGoogle Scholar
• Guner OF. Metric for analyzing hits list pharmacophores. In: Guner OF, ed. Pharmacophore perception, development and use in drug design. La Jolla (CA): International University Line; 2000: 191–211.
   Google Scholar
• Kalva S, Azhagiya Singam ER, Rajapandian V, et al. Discovery of potent inhibitor for matrix metalloproteinase-9 by pharmacophore based modeling and dynamics simulation studies. J Mol Graph Model 2014;49:25–37.
   PubMed Web of Science ®Google Scholar
• Sun H. Pharmacophore-based virtual screening. Curr Med Chem 2008;15:1018–24.
   PubMed Web of Science ®Google Scholar
• Wang J, Hou T. Develop and test a solvent accessible surface area-based model in conformational entropy calculations. J Chem Inf Model 2012;52:1199–212.
   PubMed Web of Science ®Google Scholar
• Shen M, Zhou S, Li Y, et al. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design. Mol Biosyst 2013;9:2435–46.
   PubMed Web of Science ®Google Scholar
• Butina D, Segall MD, Frankcombe K. Predicting ADME properties in silico: methods and models. Drug Discov Today 2002;7:S83–8.
   PubMed Web of Science ®Google Scholar